Baillie Gifford & Co
IRWD icon

Baillie Gifford & Co’s Ironwood Pharmaceuticals IRWD Stock Holding History

Baillie Gifford & Co’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-935
Closed -$12K – 507
2021
Q3 		$12K Hold
935
– – ﹤0.01% 431
2021
Q2 		$12K Hold
935
– – ﹤0.01% 417
2021
Q1 		$10K Sell
935
-55
-6% -$581 ﹤0.01% 405
2020
Q4 		$11K Buy
+990
New +$10.8K ﹤0.01% 377

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Baillie Gifford & Co's IRWD Position: Q4 2021 in Review

Baillie Gifford & Co sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2021, closing a stake of 935 shares — an estimated $12K sold.

Baillie Gifford & Co first reported a position in IRWD in Q4 2020 and held it in 4 quarters. The position peaked at $12K in Q3 2021. 212 funds tracked by Wall St. Rank hold IRWD as of Q4 2021.

  • Baillie Gifford & Co reported no remaining Ironwood Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Baillie Gifford & Co sold 935 Ironwood Pharmaceuticals shares in Q4 2021, an estimated $12K.
  • Baillie Gifford & Co first reported a position in Ironwood Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Baillie Gifford & Co's Ironwood Pharmaceuticals position peaked at $12K in Q3 2021.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2021.

Based on Baillie Gifford & Co's 13F filing for Q4 2021, filed 20 Jan 2022.